TRIL Trillium Therapeutics Inc.

2.77
+0.1  (+4%)
Previous Close 2.67
Open 2.73
Price To Book -11.54
Market Cap 77,667,562
Shares 28,038,831
Volume 2,112,562
Short Ratio
Av. Daily Volume 3,533,406
Stock charts supplied by TradingView

NewsSee all news

  1. Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

    CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  2. Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

    Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies at doses up to 0.5

  3. Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,

  4. Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

    TORONTO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has

  5. Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

    TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial ongoing. ORR 18-29%. Update due mid-2020.
TTI-621-01
Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)
Phase 1 trial ongoing.
TTI-621-02
Solid tumors
Phase 1a/b update due mid-2020.
TTI-622
Refractory lymphoma or multiple myeloma

Latest News

  1. Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

    CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  2. Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

    Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies at doses up to 0.5

  3. Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,

  4. Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

    TORONTO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has

  5. Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

    TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr.

  6. Trillium Therapeutics To Present At Investor Conference

    TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company